Phaseline

Companies › Stamford Pharmaceuticals

Stamford Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Mar 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SP-002
Replication deficient adenovirus-5 encoding human interferon gamma (IFNγ)
IFNGPhase 2Basal Cell CarcinomaMar 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06344052SP-002Phase 2Basal Cell CarcinomaOncologyMar 2029

Targets

IFNG (1)

Companies with the same targets

–

Companies built like this

NanoEcho Syncromune Galecto Biotech VSPharmTech BPGbio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.